43,835 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 43,835 shares of the biopharmaceutical company's stock, valued at approximately $2,096,000.

Several other large investors also recently bought and sold shares of HALO. GSA Capital Partners LLP acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth about $217,000. CIBC Asset Management Inc acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth about $211,000. Sheaff Brock Investment Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 7.7% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company's stock worth $407,000 after buying an additional 507 shares during the period. Koa Wealth Management LLC boosted its stake in shares of Halozyme Therapeutics by 1.2% during the third quarter. Koa Wealth Management LLC now owns 74,483 shares of the biopharmaceutical company's stock worth $4,263,000 after buying an additional 915 shares during the period. Finally, Natixis Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 86.7% during the third quarter. Natixis Advisors LLC now owns 121,560 shares of the biopharmaceutical company's stock worth $6,958,000 after buying an additional 56,461 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on HALO shares. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Benchmark reissued a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of "Moderate Buy" and an average target price of $62.78.

Remove Ads

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 31,697 shares of company stock valued at $1,754,451. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock traded up $1.76 during mid-day trading on Wednesday, reaching $64.30. The company had a trading volume of 1,346,942 shares, compared to its average volume of 1,311,085. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The company has a market capitalization of $7.92 billion, a P/E ratio of 18.75, a P/E/G ratio of 0.42 and a beta of 1.32. The stock's 50-day simple moving average is $57.53 and its 200-day simple moving average is $54.61.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.